A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Trial Profile

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Acronyms EXPEDITION; FLIGHT-3
  • Sponsors Novartis
  • Most Recent Events

    • 24 May 2017 Results assessing improvement in lung function with indacaterol/glycopyrrolate twice daily versus indacaterol once daily in patients with moderate-to-severe COPD, presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results from analysis of FLIGHT trials (FLIGHT1, FLIGHT2 and FLIGHT3 studies) presented at the 113th International Conference of the American Thoracic Society
    • 23 May 2017 According to a Sunovion Pharmaceuticals media release, data from this study was presented at the 2017 American Thoracic Society International Conference (ATS 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top